janssen_latest_logo_on_sign_closer

Janssen & Vor Biopharma to collaborate on acute myeloid leukemia treatment

pharmafile | July 12, 2021 | News story | Sales and Marketing  

Vor Biopharma and Janssen have announced a collaboration to develop engineered hematopoietic stem cell transplants combined with a bi-specific antibody therapy for acute myeloid leukemia (AML).

Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vor’s “invisible” eHSC transplant platform with one of Janssen’s bi-specific antibodies in development for AML.

Tirtha Chakraborty, Chief Scientific Officer at Vor, said: “We are thrilled to enter into this collaboration with Janssen as we continue to explore our platform’s potential to pair with a broad spectrum of targeted therapy modalities for the treatment of patients with blood cancer.

Advertisement

“We believe this unique combination will leverage each technology’s strengths, while protecting patients against off-target effects of these powerful immunotherapies.”

The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms. No financial terms were disclosed.

Vor Biopharma is a cell-therapy company founded by PureTech Health PLC, working with engineered hematopoietic stem cell (eHSC) therapies to create treatment-resistant transplants.

 Kat Jenkins

Related Content

No items found
The Gateway to Local Adoption Series

Latest content